SPDR S&P Biotech ETF (XBI) Stock Price, News, Quotes-Moomoo

US ETFDetailed Quotes

XBI SPDR S&P Biotech ETF

Watchlist

91.280
+1.470+1.64%

Close Dec 20 16:00 ET

91.970High89.340Low

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

SPDR S&P Biotech ETF Declares Quarterly Distribution of $0.0027
Seeking Alpha5minutes ago
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Seeking Alpha16:12 ET
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Benzinga14:51 ET
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Seeking AlphaDec 22 10:12 ET
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
BenzingaDec 22 09:51 ET
SPDR S&P Biotech ETF To Go Ex-Dividend On December 23rd, 2024 With 0.00269 USD Dividend Per Share
Moomoo NewsDec 20 19:40 ET

Comments

topcing

Nov 4 21:29

$SPDR S&P Biotech ETF (XBI.US)$ yea

股勇者

Oct 25 10:17

$SPDR S&P Biotech ETF (XBI.US)$ 100 month end? ok?

Bellaah

Sep 11 11:10

$SPDR S&P Biotech ETF (XBI.US)$ 95

Moomoo Learn

Sep 6 03:05

Columns Navigating the wave of lower interest rates

Given the strong market expectations for a Federal Reserve rate cut, as indicated by the CME data with a 57% chance for a 25-basis-point reduction and a 43% chance for a 50-basis-point cut in September, investors are poised to reconsider their strategies.
With the Fed's September meeting likely to deliver a rate decrease, the question arises: how should investors allocate assets during an interest rate cut cycle? Let's delve into the tactics and consid...

CPI hits 3-year low: How will it sway the Fed rate decision?

frankinglily

Aug 25 22:03

Argument:
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...

Powell said it's time to cut: Will the market go wild?